Canadian Pacific Kansas City Limited Common Shares vs Cassava Sciences Inc — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $84.07 (market cap $73.98B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 1877.7× Cassava Sciences Inc's market cap, and Canadian Pacific Kansas City Limited Common Shares pays a 0.9% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CP | FLNA | |
|---|---|---|
Market Cap | $73.98B | $39.40M |
Volume | 1,669,828 | 759,018 |
Sector | Industrials | Health |
52-Week High | $96.69 | $4.64 |
52-Week Low | $68.88 | $0.68 |
Enterprise Value | $91.36B | -$43.28M |
Dividend Yield | 0.9% | — |
Typical Hold Time | — | 37 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →